Urinary incontinence, or leakage of urine, is a very common condition for women of all ages, ethnicities and backgrounds.

The goal of this assessment will be to focus on the role of PTNS in the treatment of overactive bladder.

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Modern treatment approaches offer numerous options ... Acupuncture shows promise in reducing overactive bladder symptoms and stress incontinence. However, results vary among individuals, and more ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

Depositphotos *We spoke to actress, advocate, and philanthropist Holly Robinson Peete about her current projects and her journey with overactive ... information on treatment options, such as ...

Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.